Drugmakers

COVID-19

After Slow Start, States Are Flush With COVID-19 Antiviral Pills. But Federal Data Shows Some Are Slow to Give Them Out

COVID-19

2 in 3 Democrats and 2 in 5 Republicans Back Proposal to Waive COVID-19 Vaccine Patent Rights

Drug Pricing

Incoming PhRMA Chair Expects Drugmakers to Face ‘Some Pain’ in 2022 Amid Reform and Efforts to Rebuild Patient Trust

Drugmakers

Clinical Trials Are Slow and Expensive. Industry Leaders Want That to Change in 2022

COVID-19

The FDA Is Expected to Authorize COVID-19 Antiviral Pills. 3 in 4 Adults Say They’d Take Them if They Got Sick

Drugmakers

As Threat of Antibiotic Resistance Mounts, Biotechs Are Running Out of Cash and Time

Congressional Politics

In Oklahoma, A Warning for Proponents of Value-Based Pharma Payment

Congressional Politics

As Drug Prices Soar, Policymakers Eye Dose of Government Intervention